Rhythm Pharma CEO exercises, sells 50K shares
Rhythm Pharmaceuticals’ CEO exercised long‑standing stock options and sold 50,000 shares in pre‑planned trades under a Rule 10b5‑1 plan.
Rhea-AI Filing Summary
For Rhythm Pharmaceuticals, Inc. (RYTM), President and CEO David P. Meeker reported exercising options for 50,000 shares of common stock at an exercise price of $6.05 per share on September 14, 2026, and selling 50,000 shares in multiple transactions on the same day. The option exercise relates to awards granted in February 2017, and the exercise and sales were carried out under a Rule 10b5-1 trading plan adopted on June 15, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 50,000 shares ($4.83M approx. pre-tax spread)
Exercise and Sale
7 txns
Insider
Meeker David P
Role
President and CEO
Sold
50,000 shs ($5.13M)
Approx. gross sale proceeds
$5.13M
Approx. exercise cost
$303K
Approx. pre-tax spread
$4.83M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) F8 | 50,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 50,000 | $6.05 | $303K |
| Sale | Common Stock F1, F3 | 6,439 | $101.7464 | $655K |
| Sale | Common Stock F1, F4 | 30,746 | $102.347 | $3.15M |
| Sale | Common Stock F1, F5 | 8,698 | $103.43 | $900K |
| Sale | Common Stock F1, F6 | 1,817 | $104.5487 | $190K |
| Sale | Common Stock F1, F7 | 2,300 | $105.19 | $242K |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 15,431 contracts (Direct);
Common Stock — 239,258 shares (Direct)
Footnotes (8)
- F1. The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026.
- F2. Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026.
- F3. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8. The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017.
Key Figures
Options exercised: 50,000 shares
Exercise price: $6.05 per share
Shares sold: 50,000 shares
+5 more
8 metrics
Options exercised
50,000 shares
Options for Rhythm Pharmaceuticals common stock exercised on September 14, 2026
Exercise price
$6.05 per share
Exercise price of options exercised for 50,000 shares
Shares sold
50,000 shares
Total Rhythm Pharmaceuticals shares sold in multiple transactions on September 14, 2026
Weighted average sale price (first tranche)
$101.7464 per share
6,439 shares sold with trades in the range $100.96–$101.95
Weighted average sale price (largest tranche)
$102.3470 per share
30,746 shares sold with trades in the range $101.96–$102.94
Highest weighted average sale price
$105.1900 per share
2,300 shares sold with trades in the range $105.00–$105.31
Remaining derivative securities
15,431 options
Options of the same type directly held after the reported exercise
ESPP shares included
242 shares
Common shares acquired under the employee stock purchase plan on February 28, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average price, employee stock purchase plan, employee stock option
4 terms
Rule 10b5-1 trading plan regulatory
"The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
employee stock purchase plan financial
"Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
employee stock option financial
"The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017."
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did RYTM’s CEO report on September 14, 2026?
David P. Meeker reported exercising 50,000 stock options for Rhythm Pharmaceuticals common stock at an exercise price of $6.05 per share and selling 50,000 shares of common stock in multiple transactions on September 14, 2026.
Were the RYTM CEO’s transactions made under a Rule 10b5-1 plan?
Yes. The filing states that the option exercise and related sales were effected pursuant to a Rule 10b5-1 trading plan adopted by David P. Meeker on June 15, 2026.
What stock options did the RYTM CEO exercise in this Form 4?
David P. Meeker exercised options for 50,000 shares of Rhythm Pharmaceuticals common stock at an exercise price of $6.05 per share. These options were granted on February 8, 2017 and vested in three equal annual installments measured from January 6, 2017.
How many derivative securities remain after the RYTM CEO’s option exercise?
After exercising 50,000 options, the filing reports that 15,431 derivative securities of the same option type remain directly held by David P. Meeker.
Does the RYTM Form 4 mention purchases under an employee stock purchase plan?
Yes. A footnote states that the reported holdings include 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on February 28, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
